Scopus
🔓 Açık Erişim YÖKSİS Eşleşti
Pentoxifylline in Dogs With Osteoarthritis: Comparative Treatment and Efficacy Analysis With Meloxicam
Veterinary Medicine and Science · Temmuz 2025
YÖKSİS Kayıtları
Pentoxifylline in Dogs With Osteoarthritis: Comparative Treatment and Efficacy Analysis With Meloxicam
Veterinary Medicine and Science · 2025 SCI-Expanded
DOKTOR ÖĞRETİM ÜYESİ NURİZA ZAMIRBEKOVA ERDOĞAN →
Pentoxifylline in Dogs With Osteoarthritis: Comparative Treatment and Efficacy Analysis With Meloxicam
VETERINARY MEDICINE AND SCIENCE · 2025 SCI
PROFESÖR BURAK DİK →
Makale Bilgileri
DergiVeterinary Medicine and Science
Yayın TarihiTemmuz 2025
Cilt / Sayfa11
Scopus ID2-s2.0-105006816395
Erişim🔓 Açık Erişim
Özet
Background: Osteoarthritis is a chronic joint disease that affects dogs and humans alike, with nonsteroidal anti-inflammatory drugs (NSAIDs) being the primary drug treatment for pain relief. This study hypothesised that pentoxifylline could be a potent therapeutic option for canine osteoarthritis, offering superior benefits compared to meloxicam. The study aimed to mitigate inflammation and degeneration, safeguard joint integrity, and assess pentoxifylline's potential as a safer and more effective alternative to NSAIDs in osteoarthritis management. Methods: 12 dogs with stifle osteoarthritis were divided into two groups: meloxicam (0.1 mg/kg, subcutaneous) and pentoxifylline (10 mg/kg, intramuscular). Clinical, radiological and biochemical examinations were conducted on days 0, 15, 30 and 60. Results: The pain scores were significantly lower in the meloxicam group on days 30 and 60 (p < 0.05). However, both groups had similar scores for other clinical evaluations (p > 0.05). Serum C-reactive protein (CRP) levels were lower in the pentoxifylline group on days 15 and 30, and serum IL-1β levels were lower on days 15, 30 and 60 (p < 0.05). Moreover, cartilage oligomeric matrix protein (COMP) and bone alkaline phosphatase (bALP) levels in the pentoxifylline group showed a significant reduction on day 15 (p < 0.05). Pentoxifylline reduced osteocalcin in serum and hyaluronic acid concentrations in synovial fluid on days 15 and 30 (p < 0.05). However, the level of cross-linked C-telopeptide of type 2 collagen in urine significantly decreased following meloxicam treatment. Conclusion: Meloxicam relieves pain by protecting joint cartilage, while even low doses of pentoxifylline enhance joint perfusion and combat inflammation. Future research should explore higher pentoxifylline doses and its potential synergy with NSAIDs for superior osteoarthritis management.
Yazarlar (5)
1
Kurtuluş Parlak
ORCID: 0000-0002-8656-037X
2
Nuriza Zamirbekova Erdogan
ORCID: 0000-0003-4465-5511
3
T. M. Parlak
4
Elgin Orçum Uzunlu
ORCID: 0000-0001-5356-8968
5
Burak Dik
Anahtar Kelimeler
dog
meloxicam
pentoxifylline
stifle osteoarthritis
Kurumlar
Selçuk Üniversitesi
Selçuklu Turkey